 Integra Lifesciences Holdings Corp NASDAQ: IART reported Q4 adjusted EPS 0.84 better than the consensus estimate of 0.73 and revenues of 388.6 million in line with expectations. Revenues declined 1.6 YY on a reported basis and a decrease of 1.5 on an organic basis, as the COVID-19 pandemic negatively impacted the surgical procedure volumes. 